Non Interventional Study Aimed to Describe the Management of Relapse or Refractory Chronic Lymphocytic Leukemia (CLL) Patients Retreated by MabThera
Phase of Trial: Phase IV
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Roche
- 21 Mar 2017 Status changed from active, no longer recruiting to completed.
- 26 Jan 2015 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
- 26 Jan 2015 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.